CRISPR gene editing is starting to show real promise against type 1 diabetes. In 2025, doctors in Sweden reported that donor insulin cells, edited with CRISPR so the immune system could not see them, survived and worked in a patient who took no immune suppressing drugs. More than a year later, those cells are still working. Here is what that study showed, who else is in the race and what it does and does not mean for people living with type 1 diabetes in October 2026.
The problem CRISPR is trying to solve
In type 1 diabetes, the immune system destroys the beta cells in the pancreas that make insulin. People then depend on insulin injections or pumps for life. Replacing those cells is an old idea. Transplants of donor islets, the clusters that contain beta cells, can work, and the FDA approved a donor islet therapy called Lantidra in 2023 for certain adults with severe low blood sugar episodes.
The catch is rejection. Transplanted cells are attacked twice, once as foreign tissue and again by the autoimmune response that caused the disease. That means lifelong immunosuppressive drugs, which raise the risk of infections and other side effects. For most patients, that trade is not worth it. Gene editing aims to remove the need for those drugs entirely.
What the Sana study found
Researchers at Uppsala University Hospital in Sweden, working with Sana Biotechnology, took islet cells from a deceased donor and edited them with a CRISPR enzyme called Cas12b. The edits removed the HLA class I and II markers that immune cells use to spot foreign tissue and added extra CD47, a signal that tells other immune cells to back off. Sana calls cells like these hypoimmune.
The cells were injected into the forearm muscle of one adult with long standing type 1 diabetes, with no immunosuppressive drugs at all. The results, published in a major peer reviewed medical journal in August 2025, showed:
- C peptide, a marker of the body’s own insulin production, appeared in the blood after transplant and rose after meals.
- Imaging showed the cells surviving at the injection site.
- No immune attack against the edited cells was detected.
- No serious adverse events were linked to the treatment.
In 2026, Sana reported that the cells were still surviving and producing insulin 14 months after the transplant, with no safety issues. That longer follow up was also published in the same journal.
Who else is working on it
Next candidate SC451 uses hypoimmune islet cells grown from stem cells instead of donors. Sana says it expects to file with the FDA and start a Phase 1/2 trial as early as 2026, with Mayo Clinic as a partner.
Earlier tested edited stem cell derived cells inside an implanted device. Its current candidate, CTX213, uses edited stem cells without a device and is moving toward the clinic after animal studies.
Licensed CRISPR technology for hypoimmune cells in 2023 and lists gene edited islet cells among the approaches it is exploring.
Vertex also has the most advanced cell therapy overall, zimislecel, but it is not gene edited and still requires immunosuppression. In 2025 it reported that 10 of 12 fully dosed participants with a year of follow up no longer needed insulin injections. In January 2026, Vertex said it had completed enrollment in its pivotal study but temporarily postponed finishing dosing while it reviewed a manufacturing question.
How the approaches compare
| Approach | Immune drugs needed? | Stage in October 2026 |
|---|---|---|
| Donor islet transplant (Lantidra) | Yes | FDA approved for a narrow group |
| Stem cell islets (zimislecel) | Yes | Pivotal trial |
| CRISPR edited donor islets (UP421) | No | One patient study |
| CRISPR edited stem cell islets (SC451, CTX213) | Goal is no | Preparing for first human trials |
Stem cells matter because donor organs are scarce. If edited cells can be grown in a lab at scale, one manufacturing process could, in theory, supply many patients.
FAQ
Is CRISPR a cure for type 1 diabetes?
Not yet. The results so far show that edited cells can survive without immune drugs, but no trial has shown that a CRISPR therapy can safely replace insulin for many people over the long term.
Can I join a trial?
Trials are small and have strict criteria. Ask your endocrinologist, who can help you judge whether any study fits your situation.
When could a treatment be available?
No company has given a realistic approval date for a gene edited diabetes therapy. Human trials of stem cell versions are only starting, and those usually take years.
The verdict
Hiding transplanted insulin cells from the immune system with CRISPR has moved from theory to a working result in a real patient, and that is genuine progress. It is still early, small and unproven at scale. Keep following the trials, and talk to your doctor before making any change to how you manage your diabetes.
Updated October 2026: covers the Sana hypoimmune islet study through 14 months, the CRISPR Therapeutics and Vertex programs, and where each approach stands.
Featured photo: Julia Koblitz on Unsplash.
About this article: GeekBlog covers U.S. technology news, AI, phones, smartwatches and gaming. Every story is written and checked under our Editorial Policy. Spotted a mistake or have a story tip? Contact our editors.

